Hydrojet-based delivery of footprint-free iPSC-derived cardiomyocytes into porcine myocardium.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 10 2020
08 10 2020
Historique:
received:
20
04
2020
accepted:
14
09
2020
entrez:
9
10
2020
pubmed:
10
10
2020
medline:
15
12
2020
Statut:
epublish
Résumé
The reprogramming of patient´s somatic cells into induced pluripotent stem cells (iPSCs) and the consecutive differentiation into cardiomyocytes enables new options for the treatment of infarcted myocardium. In this study, the applicability of a hydrojet-based method to deliver footprint-free iPSC-derived cardiomyocytes into the myocardium was analyzed. A new hydrojet system enabling a rapid and accurate change between high tissue penetration pressures and low cell injection pressures was developed. Iron oxide-coated microparticles were ex vivo injected into porcine hearts to establish the application parameters and the distribution was analyzed using magnetic resonance imaging. The influence of different hydrojet pressure settings on the viability of cardiomyocytes was analyzed. Subsequently, cardiomyocytes were delivered into the porcine myocardium and analyzed by an in vivo imaging system. The delivery of microparticles or cardiomyocytes into porcine myocardium resulted in a widespread three-dimensional distribution. In vitro, 7 days post-injection, only cardiomyocytes applied with a hydrojet pressure setting of E20 (79.57 ± 1.44%) showed a significantly reduced cell viability in comparison to the cells applied with 27G needle (98.35 ± 5.15%). Furthermore, significantly less undesired distribution of the cells via blood vessels was detected compared to 27G needle injection. This study demonstrated the applicability of the hydrojet-based method for the intramyocardial delivery of iPSC-derived cardiomyocytes. The efficient delivery of cardiomyocytes into infarcted myocardium could significantly improve the regeneration.
Identifiants
pubmed: 33033281
doi: 10.1038/s41598-020-73693-x
pii: 10.1038/s41598-020-73693-x
pmc: PMC7546722
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16787Références
Wong, N. D. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat. Rev. Cardiol. 11(5), 276 (2014).
pubmed: 24663092
doi: 10.1038/nrcardio.2014.26
pmcid: 24663092
Cahill, T. J., Choudhury, R. P. & Riley, P. R. Heart regeneration and repair after myocardial infarction: Translational opportunities for novel therapeutics. Nat. Rev. Drug Discov. 16(10), 699 (2017).
pubmed: 28729726
doi: 10.1038/nrd.2017.106
pmcid: 28729726
Li, Z. & Guan, J. Hydrogels for cardiac tissue engineering. Polymers 3(2), 740–761 (2011).
doi: 10.3390/polym3020740
Lázár, E., Sadek, H. A. & Bergmann, O. Cardiomyocyte renewal in the human heart: Insights from the fall-out. Eur. Heart J. 38(30), 2333–2342 (2017).
pubmed: 28810672
pmcid: 5837331
doi: 10.1093/eurheartj/ehx343
Talman, V. & Ruskoaho, H. Cardiac fibrosis in myocardial infarction—From repair and remodeling to regeneration. Cell Tissue Res. 365(3), 563–581 (2016).
pubmed: 27324127
pmcid: 5010608
doi: 10.1007/s00441-016-2431-9
Ptaszek, L. M. et al. Towards regenerative therapy for cardiac disease. Lancet 379(9819), 933–942 (2012).
pubmed: 22405796
doi: 10.1016/S0140-6736(12)60075-0
pmcid: 22405796
Karantalis, V. et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting. Circ. Res. 114(8), 1302–1310 (2014).
pubmed: 24565698
pmcid: 4104798
doi: 10.1161/CIRCRESAHA.114.303180
Houtgraaf, J. H. et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 59(5), 539–540 (2012).
pubmed: 22281257
doi: 10.1016/j.jacc.2011.09.065
pmcid: 22281257
Menasche, P. et al. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial—First randomized placebo-controlled study of myoblast transplantation. Circulation 117(9), 1189–1200 (2008).
pubmed: 18285565
doi: 10.1161/CIRCULATIONAHA.107.734103
pmcid: 18285565
Assmus, B. et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106(24), 3009–3017 (2002).
pubmed: 12473544
doi: 10.1161/01.CIR.0000043246.74879.CD
pmcid: 12473544
Makkar, R. R. et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 379(9819), 895–904 (2012).
pubmed: 22336189
pmcid: 4326004
doi: 10.1016/S0140-6736(12)60195-0
Beer, L. et al. Peripheral blood mononuclear cell secretome for tissue repair. Apoptosis 21(12), 1336–1353 (2016).
pubmed: 27696124
pmcid: 5082595
doi: 10.1007/s10495-016-1292-8
Gnecchi, M. et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 103(11), 1204–1219 (2008).
pubmed: 19028920
pmcid: 2667788
doi: 10.1161/CIRCRESAHA.108.176826
Yoon, Y.-S. et al. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation 109(25), 3154–3157 (2004).
pubmed: 15197139
doi: 10.1161/01.CIR.0000134696.08436.65
pmcid: 15197139
Breitbach, M. et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110(4), 1362–1369 (2007).
pubmed: 17483296
doi: 10.1182/blood-2006-12-063412
pmcid: 17483296
Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663–676 (2006).
pubmed: 16904174
doi: 10.1016/j.cell.2006.07.024
pmcid: 16904174
Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861–872 (2007).
pubmed: 18035408
doi: 10.1016/j.cell.2007.11.019
pmcid: 18035408
Yu, J., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science318(5858), 1917–1920 (2007).
Kaji, K. et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458(7239), 771 (2009).
pubmed: 19252477
pmcid: 2667910
doi: 10.1038/nature07864
Woltjen, K. et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458(7239), 766 (2009).
pubmed: 19252478
pmcid: 3758996
doi: 10.1038/nature07863
Zhou, W. & Freed, C. R. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem cells 27(11), 2667–2674 (2009).
pubmed: 19697349
doi: 10.1002/stem.201
pmcid: 19697349
Seki, T. et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7(1), 11–14 (2010).
pubmed: 20621043
doi: 10.1016/j.stem.2010.06.003
pmcid: 20621043
Narsinh, K.H., et al. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors.Nat. Protocols6(1), 78 (2011).
Warren, L. et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7(5), 618–630 (2010).
pubmed: 20888316
pmcid: 3656821
doi: 10.1016/j.stem.2010.08.012
Kim, D. et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4(6), 472 (2009).
pubmed: 19481515
pmcid: 2705327
doi: 10.1016/j.stem.2009.05.005
Steinle, H. et al. Reprogramming of urine-derived renal epithelial cells into iPSCs using srRNA and consecutive differentiation into beating cardiomyocytes. Mol. Ther. Nucleic Acids 17, 907–921 (2019).
pubmed: 31476669
pmcid: 6723182
doi: 10.1016/j.omtn.2019.07.016
Ye, L. et al. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell 15(6), 750–761 (2014).
pubmed: 25479750
pmcid: 4275050
doi: 10.1016/j.stem.2014.11.009
Gao, L. et al. Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac cells improve recovery from myocardial infarction in swine. Circulation 137(16), 1712–1730 (2018).
pubmed: 29233823
doi: 10.1161/CIRCULATIONAHA.117.030785
pmcid: 29233823
Gerbin, K. A. et al. Enhanced electrical integration of engineered human myocardium via intramyocardial versus epicardial delivery in infarcted rat hearts. PLoS ONE 10(7), e0131446 (2015).
pubmed: 26161513
pmcid: 4498815
doi: 10.1371/journal.pone.0131446
Halbach, M. et al. Electrophysiological integration and action potential properties of transplanted cardiomyocytes derived from induced pluripotent stem cells. Cardiovasc. Res. 100(3), 432–440 (2013).
pubmed: 24042016
doi: 10.1093/cvr/cvt213
pmcid: 24042016
O'Cearbhaill, E.D., Ng, K.S., Karp, J.M. Emerging medical devices for minimally invasive cell therapy. in Mayo Clinic Proceedings. (Elsevier, London, 2014).
Jager, L. et al. A novel waterjet technology for transurethral cystoscopic injection of viable cells in the urethral sphincter complex. Neurourol. Urodyn. 39(2), 594–602 (2020).
pubmed: 31873953
doi: 10.1002/nau.24261
Aguado, B. A. et al. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng. Part A 18(7–8), 806–815 (2012).
pubmed: 22011213
doi: 10.1089/ten.tea.2011.0391
Shiba, Y. et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 538(7625), 388–391 (2016).
pubmed: 27723741
doi: 10.1038/nature19815
Chong, J. J. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510(7504), 273–277 (2014).
pubmed: 24776797
pmcid: 4154594
doi: 10.1038/nature13233
Zhao, X. et al. Comparison of non-human primate versus human induced pluripotent stem cell-derived cardiomyocytes for treatment of myocardial infarction. Stem Cell Rep. 10(2), 422–435 (2018).
doi: 10.1016/j.stemcr.2018.01.002
Chow, A. et al. Human induced pluripotent stem cell-derived cardiomyocyte encapsulating bioactive hydrogels improve rat heart function post myocardial infarction. Stem Cell Rep. 9(5), 1415–1422 (2017).
doi: 10.1016/j.stemcr.2017.09.003
Tabei, R. et al. Development of a transplant injection device for optimal distribution and retention of human induced pluripotent stem cellderived cardiomyocytes. J. Heart Lung Transplant 38(2), 203–214 (2019).
pubmed: 30691596
doi: 10.1016/j.healun.2018.11.002
Amer, M. H. et al. Translational considerations in injectable cell-based therapeutics for neurological applications: Concepts, progress and challenges. NPJ Regen. Med. 2, 23 (2017).
pubmed: 29302358
pmcid: 5677964
doi: 10.1038/s41536-017-0028-x
Fukushima, S. et al. Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 115(17), 2254–2261 (2007).
pubmed: 17438152
doi: 10.1161/CIRCULATIONAHA.106.662577
pmcid: 17438152
Nagaya, N. et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am. J. Physiol. Heart Circ. Physiol. 287(6), H2670–H2676 (2004).
pubmed: 15284059
doi: 10.1152/ajpheart.01071.2003
pmcid: 15284059
Luger, D. et al. Intravenously delivered mesenchymal stem cells: Systemic anti-inflammatory effects improve left ventricular dysfunction in acute myocardial infarction and ischemic cardiomyopathy. Circ. Res. 120(10), 1598–1613 (2017).
pubmed: 28232595
doi: 10.1161/CIRCRESAHA.117.310599
pmcid: 28232595
Chen, S. L. et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardiol. 94(1), 92–95 (2004).
pubmed: 15219514
doi: 10.1016/j.amjcard.2004.03.034
pmcid: 15219514
Strauer, B. E. et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: The IACT Study. J. Am. Coll. Cardiol. 46(9), 1651–1658 (2005).
pubmed: 16256864
doi: 10.1016/j.jacc.2005.01.069
pmcid: 16256864
Bartunek, J. et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: Feasibility and safety. Circulation 112(9 Suppl), I178–I183 (2005).
pubmed: 16159812
pmcid: 16159812
Katritsis, D. G. et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc. Interv. 65(3), 321–329 (2005).
pubmed: 15954106
doi: 10.1002/ccd.20406
pmcid: 15954106
Plewka, M. et al. Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction. Am. J. Cardiol. 104(10), 1336–1342 (2009).
pubmed: 19892047
doi: 10.1016/j.amjcard.2009.06.057
pmcid: 19892047
Otto Beitnes, J. et al. Intramyocardial injections of human mesenchymal stem cells following acute myocardial infarction modulate scar formation and improve left ventricular function. Cell Transplant 21(8), 1697–1709 (2012).
pubmed: 22410280
doi: 10.3727/096368911X627462
pmcid: 22410280
Pokorney, S. D. et al. Infarct healing is a dynamic process following acute myocardial infarction. J. Cardiovasc. Magn. Reson. 14(1), 62 (2012).
pubmed: 22937750
pmcid: 3443460
doi: 10.1186/1532-429X-14-62
Ingkanisorn, W. P. et al. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J. Am. Coll. Cardiol. 43(12), 2253–2259 (2004).
pubmed: 15193689
doi: 10.1016/j.jacc.2004.02.046
pmcid: 15193689
Lund, G. K. et al. Prediction of left ventricular remodeling and analysis of infarct resorption in patients with reperfused myocardial infarcts by using contrast-enhanced MR imaging. Radiology 245(1), 95–102 (2007).
pubmed: 17885184
doi: 10.1148/radiol.2451061219
pmcid: 17885184
Sheng, C. C., Zhou, L. & Hao, J. Current stem cell delivery methods for myocardial repair. Biomed. Res. Int. 2013, 547902 (2013).
pubmed: 23509740
pmcid: 23509740
Patel, A. N. et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J. Thorac. Cardiovasc. Surg. 130(6), 1631–1638 (2005).
pubmed: 16308009
doi: 10.1016/j.jtcvs.2005.07.056
pmcid: 16308009
Pompilio, G. et al. Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: Preliminary results. Thorac. Cardiovasc. Surg. 56(2), 71–76 (2008).
pubmed: 18278680
doi: 10.1055/s-2007-989351
pmcid: 18278680
Perin, E. C. et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107(18), 2294–2302 (2003).
pubmed: 12707230
doi: 10.1161/01.CIR.0000070596.30552.8B
pmcid: 12707230
Fuchs, S. et al. Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am. J. Cardiol. 97(6), 823–829 (2006).
pubmed: 16516583
doi: 10.1016/j.amjcard.2005.09.132
pmcid: 16516583
Dohmann, H. F. et al. Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure: postmortem anatomicopathologic and immunohistochemical findings. Circulation 112(4), 521–526 (2005).
pubmed: 16027258
doi: 10.1161/CIRCULATIONAHA.104.499178
pmcid: 16027258
Tse, H. F. et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur. Heart J. 28(24), 2998–3005 (2007).
pubmed: 17984132
doi: 10.1093/eurheartj/ehm485
pmcid: 17984132
Trachtenberg, B. et al. Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. Am. Heart J. 161(3), 487–493 (2011).
pubmed: 21392602
doi: 10.1016/j.ahj.2010.11.024
pmcid: 21392602
Grossman, P. M. et al. Incomplete retention after direct myocardial injection. Catheter Cardiovasc. Interv. 55(3), 392–397 (2002).
pubmed: 11870950
doi: 10.1002/ccd.10136
pmcid: 11870950